drugset / Trial / NCT07480863
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
Phase 2
Active not recruiting
65 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
BioRay Pharmaceutical Co., Ltd. · collabInnoCare Pharma Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
In patients with previously untreated Marginal zone lymphoma (MZL), a treatment regimen of Orelabrutinib,Zuberitamab combined with Cyclophosphamide,Vincristine,Prednisoneacetatetablets is planned to be used.
Timeline
- Start
- 2025-10-01
- Primary completion
- 2029-10-01
- Completion
- 2029-10-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orelabrutinib | Small molecule | 150 mg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 100 mg | Intravenous |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |
| Background | Zuberitamab | Monoclonal antibody | 375 mg/m2 | Intravenous |